TERN Stock Discussion
Terns Pharmaceuticals, Inc. Description
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase 2a clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase 1 clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Foster City, California.
Industry: Biotechnology
Keywords: Biopharmaceutical Organ Systems Obesity Hepatitis Steatohepatitis Non Alcoholic Fatty Liver Disease Peptide Hormones Liver Bile Acid Chronic Liver Diseases Glucagon Anti Diabetic Drugs
Recent Comments
- TraderMike on IZM
- SuccessfulGerbil321 on IZM
- TraderMike on IZM
- TraderMike on Today's Outage
- Crunching_The_Market on Today's Outage
From the Blog
Popular Now
Featured Articles